Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454)- R20 - Effective October 1, 2026

Date Posted: November 5, 2026

This Billing and Coding Article has been revised under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, and NMI), and 01312 (NV).

Effective Date: Multiple dates

Summary of Changes:

Under CPT/HCPCS Codes Group 1: Codes added 0688U and 0689U. This revision is due to the 2026 Q4 CPT/HCPCS Code Update and is effective 10/01/2026.

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised third sentence to add "RaDaR". This revision is due to a new covered test that has successfully completed a TA and is effective 4/9/2026.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Nov 05 , 2026